文献速递炎症性肠病消化道肿瘤与早癌消化内镜

免疫检查点抑制剂相关结肠炎

Checkpoint Inhibitor-Induced Colitis.
PubMed 文献 · Am J Gastroenterol · 2020-01-01

本文综述了免疫检查点抑制剂相关结肠炎(IMC)的病理生理、临床表现和治疗。IMC 与炎症性肠病有相似之处,但被视为一种急性起病、快速进展的独立结肠炎类型,可导致肠穿孔和死亡。指南推荐早期内镜评估以明确诊断并及时使用糖皮质激素,一线治疗应答需早期评估以决定是否升级至生物制剂。

要点

  • IMC 是急性起病、快速进展的独立结肠炎类型,可致肠穿孔和死亡。
  • 指南推荐早期内镜评估以明确诊断并及时启动糖皮质激素治疗。
  • 一线治疗应答应早期评估,以决定是否升级至生物制剂。

核心结论

  • IMC 被视为一种与炎症性肠病不同的独立结肠炎类型,需及时识别和管理以优化结局。
  • 尽管缺乏前瞻性临床试验指导治疗,近期指南推荐早期内镜评估和及时启动糖皮质激素。
  • 大多数患者经治疗可实现症状完全缓解,后续可考虑重新挑战抗 PD-1 或抗 PD-L1 抑制剂。

研究设计与样本

  • 本综述汇总了关于免疫介导性结肠炎(IMC)的病理生理、临床表现和治疗的最新数据。

主要发现

  • IMC 的发病机制尚未完全阐明,近期研究聚焦于调节性 T 细胞与肠道微生物群的相互作用。
  • IMC 与炎症性肠病有相似之处,但被视为一种急性起病、快速进展的独立结肠炎类型,可导致肠穿孔和死亡等并发症。

关键数值与推荐

  • 近期指南推荐早期内镜评估以明确诊断,并及时启动糖皮质激素治疗。
  • 一线治疗应答应早期评估,以确定是否需要升级至生物制剂。

临床怎么用

  • 对疑似 IMC 患者应早期进行内镜评估以明确诊断。
  • 确诊后应及时启动糖皮质激素作为一线治疗。
  • 应早期评估一线治疗应答,无应答者考虑升级至生物制剂。
  • 大多数患者经治疗症状可完全缓解,后续可考虑重新挑战抗 PD-1 或抗 PD-L1 抑制剂。

局限性

  • 缺乏前瞻性临床试验指导 IMC 的治疗。
  • IMC 的发病机制尚未完全阐明。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immune checkpoint inhibitors have revolutionized treatment and overall survival for several different types of cancer. Antibodies to cytotoxic T-lymphocyte-associated protein 4 and to programmed cell death protein 1 and its ligand enhance cytotoxic T-cell survival, thus augmenting antitumor action and consequently inducing immune-related adverse events, of which the most relevant is diarrhea and colitis. This review compiles recent data on pathophysiology, clinical manifestations, and treatment of immune-mediated colitis (IMC). The pathogenesis of IMC is not completely understood, but recent studies have focused on the role of regulatory T cells and interactions with the gut microbiome. While sharing similarities with inflammatory bowel disease, IMC is considered a distinct form of colitis with acute onset and rapid progression leading to potential complications including bowel perforation and death. Prompt recognition and management of IMC is imperative for optimal outcomes. Although prospective clinical trials are lacking to guide therapy, recent guidelines recommend early endoscopic evaluation to establish the diagnosis and prompt initiation of corticosteroids. Response to first-line therapy should be assessed early to determine the need of escalation to biologic agents. With treatment, most patients will experience full resolution of symptoms, and subsequent rechallenge with anti-programmed cell death protein 1 or anti-programmed death-ligand 1 inhibitors can be considered.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Bellaguarda E, Hanauer S. Checkpoint Inhibitor-Induced Colitis. Am J Gastroenterol. 2020. PMID: 31922959. doi:10.14309/ajg.0000000000000497

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。